



















Design, Synthesis and Molecular Modeling of 
Isothiochromanone Derivatives as Acetylcholinesterase 
Inhibitors 
 
Background：A series of novel isothio- and isoselenochromanone derivatives bearing 
N-benzyl pyridinium moiety were designed, synthesized and evaluated as 
acetylcholinesterase (AChE) inhibitors. Results: Most of the target compounds 
exhibited potent anti-AChE activities with IC50 values in nanomolar ranges. Among 
them, compound 15a exhibited the most potent anti-AChE activity (IC50 = 2.7 nM), 
moderate antioxidant activity and low neurotoxicity. Moreover, the kinetic and 
docking studies revealed that compound 15a was a mixed-type inhibitor, which bound 
to PAS and CAS of AChE. Conclusion: Those results suggested that compound 15a 
might be a potential candidate for AD treatment. 
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Alzheimer's disease (AD), characterized by dementia associated the loss of memory, 
cognitive and thinking, is a progressive neurodegenerative disease [1]. In 2018, it was 
estimated that over 47 million elderly people suffered from AD, and this number will 
be tripled by 2050 to 140 million [2]. Although considerable researches have been 
devoted to the pathogenetic mechanisms of AD, the etiology of AD still remains 
unclear. Several pathological hallmarks including amyloid-β (Aβ) deposits, reduction 
of acetylcholine (ACh), τ-protein aggregation, inflammation and oxidative stress, 
have been verified to be associated with the pathogenesis of AD [3]. At present, the 
clinical approach for AD therapy has focused on increasing the brain levels of 
acetylcholine in AD patients with acetylcholinesterase inhibitors (AChEIs), such as 
donepezil, rivastigmine and galantamine [4, 5]. Accordingly, based on the cholinergic 
hypothesis, the low level of acetylcholine results in cognitive and memory deficits, 
and the improvement of the cholinergic function is an effective way to overcome the 
occurrence, symptoms and progression of AD [6].  
The crystal structure of AChE has been reported [7]. It possesses a catalytic active 
site (CAS) at the bottom of the deep narrow gorge and a peripheral anionic site (PAS) 
near the entrance of gorge which could accelerate Aβ peptide deposition and promote 
the formation of Aβ fibril [8]. Therefore, designing the dual-site AChE inhibitors 
interacting with both the CAS and PAS are meaningful for AD prevention. 
It was reported that the introduction of N-benzyl pyridinium moiety into aromatic 
scaffolds could endow them with potent AChE inhibitory activities, such as 
compounds 1-4 [9-12] (Figure 1). In our previous studies, a series of novel dual-site 
AChE inhibitors bearing the N-benzyl pyridinium moiety derived from natural 
product (±)-7, 8-Dihydroxy-3-methylisochroman-4-one [(±)-XJP] were designed and 
synthesized (Figure 2). The docking studies revealed that the presence of N-benzyl 
pyridinium moiety contributed to inhibition activities by interacting with the CAS of 
AChE, and the 4-isochromanone moiety formed stacking interactions with PAS of 
AChE [8]. To explore the effect of methoxy groups at 4-isochromanone skeleton on 
the AChE inhibitory activity, a series of derivatives have been further synthetized. The 
results showed that compound 6 exhibited the most potent anti-AChE activity and the 
highest AChE / BuChE selectivity with low neurotoxicity [13]. The structure-activity 
relationships (SARs) studies demonstrated compounds bearing methoxy group at both 
6 and 7 positions exhibited more potent anti-AChE activity than those with methoxy 
group at other positions. Although, the preliminary SARs of the 4-isochromanone 
compounds bearing N-benzyl pyridinium moiety have been studied previously, the 
effect of the oxygen atom at the 4-isochromanone skeleton on the AChE inhibitory 
activity was undefined. According to previous reports, the compounds containing 
selenium and sulfur exhibits a wide range of bioactivity, especially for antioxidation 
and neuroprotection [14, 15]. Therefore, with the goal of discovering new anti-AChE 
agents with novel skeletons as well as completing the SARs of the isochromanone 
hybrids, we further designed and synthesized a series of isothio or 
isoselenochromanone derivatives by using bioisosterism strategy (Figure 2). Herein, 
we would like to report their synthesis, AChE and BuChE inhibitory activities, 









Figure 1. Some potent anti-AChE compounds bearing benzyl pyridinium moiety 
 Figure 2. Design strategy of the target compounds  
Materials & methods 
Chemistry 
All commercially available starting materials and solvents were reagent grade and 
used without further purification unless otherwise noted. 1H NMR and 13C NMR 
spectra were recorded on Bruker-300 spectrometers using CDCl3 or DMSO-d6 as 
solvent, and were referenced to the residual peaks of CHCl3 at 7.26 ppm or DMSO-d6 
at 2.50 ppm (1H NMR) and CDCl3 at 77.23 ppm or DMSO-d6 at 39.52 ppm (
13C 
NMR). Chemical shifts (δ) were reported in ppm using TMS as an internal standard. 
Coupling constants (J) are expressed in Hz and spin multiplicities are given as s 
(singlet), d (doublet), dd (doublet of doublets), and m (multiplet). HRMS was 
performed on an Agilent 6530 Q-TOF mass spectrometer, and ESI-MS was carried 
out on an Agilent 6120 mass spectrometer. TLC was performed on Huanghai HSGF 
254 silica gel plates (China). Silica gel 60 H (200-300 mesh), manufactured by 
Qingdao Haiyang Chemical Group Co., Ltd (China) was used for general 
chromatography. 
The synthesis of intermediate 8. 
To a solution of (3,4-dimethoxyphenyl)methanol (300 mg, 1.78 mmol) in 10 mL 
acetonitrile, trimethylsilyl chloride (339 μL, 2.68 mmol) and KI (444.14 mg, 2.68 
mmol) were added and the mixture was stirred for 45 min at ambient temperature. 
Then the mixture was extracted with ethyl acetate (3 × 25 mL). The combined organic 
layers were then washed with brine (25 mL), dried over anhydrous Na2SO4, and 
concentrated in vacuo. The residues were purified by column chromatography with 
petroleum / ethyl acetate (10: 1) as eluent to afford 422.1 mg products 8 as yellow 
solids in 85.1% yields. 
The synthesis of intermediate 9. 
0.85 g (10.79 mmol) Se power was added into 20 mL deionized water at room 
temperature, and the mixture was stirred for 15 min. Sodium borohydride (612.19 mg, 
16.18 mmol) in 20 mL of deionized water was slowly added into Se power suspension 
at room temperature. After the initial vigorous reaction had subsided (20 min), one 
additional equiv of Se powder (0.85 g, 10.79 mmol) was added and a brownish red 
solution was obtained. At room temperature, a solution of 4-(iodomethyl)-1, 
2-dimethoxybenzene (3 g, 10.79 mmol) in 15 mL refined THF was added and the 
mixture was stirred for 30 min. Then the mixture was extracted with ethyl acetate (3 × 
125 mL). The combined organic layers were then washed with brine (100 mL), dried 
over anhydrous Na2SO4, and concentrated in vacuo. The residues were purified by 
column chromatography with petroleum / ethyl acetate (4: 1) as eluent to afford 4.10 
g 9 as yellow oil in 82.3% yields. 
The synthesis of intermediate 10a. 
To a solution of 4-(iodomethyl)-1,2-dimethoxybenzene (2.5 g, 8.99 mmol) in 40 
mL acetone, ethyl 2-mercaptoacetate (1.18 mL, 10.79 mmol) and K2CO3 (1.86 g, 
13.48 mmol) was added and the mixture was stirred for 5 h at room temperature. Then 
the mixture was extracted with ethyl acetate (3 × 125 mL). The combined organic 
layers were then washed with brine (100 mL), dried over anhydrous Na2SO4. The 
solvent was removed under reduced pressure to give yellow oil 10a. 
The synthesis of intermediate 10b. 
Under N2 atmosphere, to a solution of 1, 2-bis(3,4-dimethoxybenzyl)diselane (2g, 
4.35 mmol) in 30 mL MeOH, NaBH4 (246.57 mg, 6.52 mmol) was added and stirred 
for 20 min. Then ethyl 2-bromoacetate (2.4 mL, 6.52 mmol) was dropped in and the 
mixture was stirred for 1 h at room temperature. The reaction was quenched by water 
and the solvent was removed under reduced pressure. Then the mixture was extracted 
with ethyl acetate (3 × 125 mL). The combined organic layers were then washed with 
brine (100 mL), dried over anhydrous Na2SO4. The solvent was removed in vacuo to 
give yellow oil 10b. 
The synthesis of intermediates 11a and 11b. 
To the solution of intermediate 10a (2 g, 7.40 mmol) or 10b (2 g, 6.30 mmol) in 20 
mL MeOH, 5 mL 10% NaOH solution was dropped in and the mixture was stirred for 
30 min at reflux temperature. The solvent was removed under reduced pressure. The 
residues were extracted with ethyl acetate (2 × 125 mL) to remove impurities. The 
water layer was first adjusted to pH 4, and after adding water (50 mL), it was 
extracted with ethyl acetate (3 × 125 mL). The combined organic layers were then 
washed with brine (100 mL), dried over anhydrous Na2SO4. The solvent was removed 
in vacuo to afford 1.55 g 11a and 1.61 g 11b as yellow oil with yields of 86.6% and 
88.5%, respectively. 
The synthesis of intermediates 12a and 12b. 
To the solution of 11a (2 g, 8.25 mmol) or 11b (2 g, 6.92 mmol) in 20 mL dry 
dichloromethane, oxalyl dichloride (2 eq.) was added and the mixture was stirred for 
30 min at 0 ℃. Then the solvent was removed under reduced pressure. The residues 
were dissolved in 10 mL chlorobenzene, then SnCl4 (2 mL) was dropped in the 
solutions at 0 ℃ and the mixtures were stirred for 2 h at room temperature. The 
solvent was removed in vacuo. The residues were washed with saturated aqueous 
solution of NaHCO3 and the mixtures were diluted with 125 mL ethyl acetate. After 
filtering, the mixtures were washed with water (3 × 75 mL). The organic layers were 
then washed with brine (75 mL), dried over anhydrous Na2SO4, and concentrated in 
vacuo. The residues were purified by column chromatography with petroleum / ethyl 
acetate (10: 1; 4: 1) as eluent to afford 12a or 12b as white solid, yield 70.3% or 
79.1%. 
The synthesis of intermediates 13a and 13b. 
To the solutions of 12a (300 mg, 1.34 mmol) or 12b (300 mg, 1.11 mmol) and 
pyridine-4-carboxaldehyde (1.2 eq.) in 2 mL DMF, 2 mL 10% K2CO3 aqueous 
solution was dropped in slowly at 0 ℃. After stirred for 30 s - 2 min at 0 ℃, the 
reactions appeared the precipitates and the water was added into the reactions. Then 
the precipitates were collected by filtration, washed with water and dried to afford 13a 
and 13b in general yields. 
(Z)-6,7-dimethoxy-3-(pyridin-4-ylmethylene)isothiochroman-4-one (13a). 
Yield 57.9%, yellow solid; 1H NMR (300 MHz, CDCl3) δ 8.66 (d, J = 6.2 Hz, 2H), 
7.93 (s, 1H), 7.58 (s, 1H), 7.55 (d, J = 6.5 Hz, 2H), 6.68 (s, 1H), 3.96 (s, 6H), 3.95 (s, 
2H); 13C NMR (75 MHz, CDCl3) δ 180.5, 153.1, 150.0, 149.0, 142.3, 134.0, 134.0, 
131.8, 125.5, 124.0, 111.6, 109.3, 56.3, 56.2, 28.8; ESI-MS m/z 313.1 [M+H]+ 314.1.  
(Z)-6,7-dimethoxy-3-(pyridin-4-ylmethylene)isoselenochroman-4-one (13b). 
Yield 62.3%, yellow solid; 1H NMR (300 MHz, CDCl3) δ 8.68 (d, J = 6.1 Hz, 2H), 
8.24 (s, 1H), 7.53 (s, 1H), 7.44 (d, J = 6.2 Hz, 2H), 6.70 (s, 1H), 3.96 (s, 3H), 3.95 (s, 
3H), 3.93 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 182.0, 152.4, 150.1, 148.7, 143.4, 
135.1, 134.6, 131.1, 126.8, 123.3, 112.4, 109.8, 56.2, 56.2, 20.8; ESI-MS m/z 361.0 
[M+H]+ 362.0. 
The synthesis of intermediates 14a and 14b. 
To a solution of 12a (300 mg, 1.34 mmol) or 12b (300 mg, 1.11 mg) in 10 mL THF, 
NaOCH3 (3 eq.) was added at room temperature. After stirred for 30 s, the 
N-Boc-piperidine-4-carboxaldehyde (1.2 eq.) in THF (3 mL) was dropped in and the 
mixtures were stirred for 30 s - 2 min at room temperature. The mixtures were diluted 
with 10 mL water, then extracted with (3 × 25 mL) EtOAc. The combined organic 
layers were then washed with brine (50 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residues were dissolved in 10 mL DCM and CF3COOH 
was added. After stirred for 2 h, the mixtures were diluted with 25 mL saturated 
NaHCO3 solution and were extracted with DCM (3 × 25 mL). The combined organic 
layers were then washed with brine (50 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residues were purified by column chromatography with 
petroleum / ethyl acetate (1: 1) as eluent to afford 14a or 14b in general yields. 
(Z)-6,7-dimethoxy-3-(piperidin-4-ylmethylene)isothiochroman-4-one (14a). 
Yield 60.2%, yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.54 (s, 1H), 6.98 (d, J = 
8.9 Hz, 1H), 6.63 (s, 1H), 5.03 (s, 1H), 3.92 (s, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 3.47 (d, 
J = 13.1 Hz, 2H), 2.98 (s, 2H), 2.79 (s, 1H), 1.86 (d, J = 21.7 Hz, 4H); 13C NMR (75 
MHz, CDCl3) δ 180.6, 152.8, 148.7, 140.0, 134.8, 130.8, 125.7, 111.5, 109.4, 56.2, 
56.1, 43.4, 34.9, 29.7, 27.2; ESI-MS m/z 319.1 [M+H]+ 320.1. 
The synthesis of target compounds 15a – 15l. 
Under N2 atmosphere, to the solutions of 75 mg intermediate 13a, 13b, 14a or 14b 
in 8 mL acetonitrile, the proper benzyl bromide derivatives (1.1 eq.) and K2CO3 (1.5 
eq.) were added and the mixtures were stirred for 1 - 2 h at reflux temperature. Then 
the solvents were removed in vacuo and the residues were purified by column 
chromatography with petroleum / ethyl acetate (2: 1) as eluent to afford 15e, 15f, 15k 
or 15l in general yields. And the residues were purified by column chromatography 
with DCM / MeOH (30: 1) as eluent to afford 15a - 15f in low yields or 15g – 15j in 
general yields. 
(Z)-1-benzyl-4-((6,7-dimethoxy-4-oxoisothiochroman-3 
-ylidene)methyl)pyridin-1-ium bromide (15a). 
Yield 30.2 %, red solid; 1H NMR (300 MHz, DMSO-d6) δ 9.22 (d, J = 6.5 Hz, 2H), 
8.41 (d, J = 6.4 Hz, 2H), 7.96 (s, 1H), 7.61 – 7.54 (m, 2H), 7.50 (s, 1H), 7.48 – 7.46 
(m, 1H), 7.45 (d, J = 4.7 Hz, 2H), 7.13 (s, 1H), 5.87 (s, 2H), 4.32 (s, 2H), 3.90 (s, 3H), 
3.84 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 178.5, 153.2, 150.2, 148.5, 144.4, 
142.5, 134.7, 134.3, 129.3, 129.2, 128.8, 127.6, 125.8, 124.1, 110.8, 110.5, 62.7, 56.1, 
55.7, 27.3; HR-MS (ESI) m/z: calcd for C24H22BrNO3S [M-Br]
+
 404.1315, found 
404.1313. 
(Z)-4-((6,7-dimethoxy-4-oxoisothiochroman-3-ylidene)methyl)-1-(4 
fluorobenzyl)pyridin-1-ium bromide (15b). 
Yield 31.3 %, red solid; 1H NMR (300 MHz, DMSO-d6) δ 9.18 (d, J = 6.5 Hz, 2H), 
8.40 (d, J = 6.6 Hz, 2H), 7.96 (s, 1H), 7.70 – 7.59 (m, 2H), 7.44 (s, 1H), 7.36 – 7.26 
(m, 2H), 7.13 (s, 1H), 5.83 (s, 2H), 4.32 (s, 2H), 3.90 (s, 3H), 3.84 (s, 3H); 13C NMR 
(75 MHz, DMSO-d6) δ 179.0, 164.7, 161.4, 153.7, 150.7, 149.0, 144.8, 143.0, 135.2, 
132.0, 131.9, 131.1, 128.1, 126.3, 124.6, 116.8, 116.5, 112.0, 111.3, 111.0, 62.3, 56.6, 
56.1, 27.8; HR-MS (ESI) m/z: calcd for C24H21BrFNO3S [M-Br]
+
 422.1221, found 
422.1220. 
(Z)-4-((6,7-dimethoxy-4-oxoisothiochroman-3-ylidene)methyl)-1-(3-fluorobenzyl)
pyridin-1-ium bromide (15c). 
Yield 29.7 %, red solid; 1H NMR (300 MHz, DMSO-d6) δ 9.21 (d, J = 6.5 Hz, 2H), 
8.42 (d, J = 6.4 Hz, 2H), 7.97 (s, 1H), 7.50 (d, J = 9.2 Hz, 2H), 7.43 (d, J = 6.3 Hz, 
2H), 7.27 (s, 1H), 7.13 (s, 1H), 5.86 (s, 2H), 4.32 (s, 2H), 3.90 (s, 3H), 3.84 (s, 3H)；
HR-MS (ESI) m/z: calcd for C24H21BrFNO3S [M-Br]
+
 422.1221, found 422.1223. 
(Z)-4-((6,7-dimethoxy-4-oxoisothiochroman-3-ylidene)methyl)-1-(2-fluorobenzyl)
pyridin-1-ium bromide (15d). 
Yield 33.1 %, red solid; 1H NMR (300 MHz, DMSO-d6) δ 9.13 (d, J = 6.5 Hz, 2H), 
8.42 (d, J = 6.5 Hz, 2H), 7.97 (s, 1H), 7.67 – 7.62 (m, 1H), 7.56 – 7.52 (m, 1H), 7.45 
(s, 1H), 7.35 (d, J = 6.9 Hz, 2H), 7.14 (s, 1H), 5.95 (s, 2H), 4.33 (s, 2H), 3.90 (s, 3H), 
3.85 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 179.0, 162.6, 159.3, 153.7, 151.0, 
149.1, 145.1, 144.4, 143.2, 143.2, 135.2, 132.6, 132.5, 132.0, 128.0, 126.2, 125.8, 
124.6, 121.8, 121.6, 116.6, 116.4, 111.3, 111.0, 57.8, 56.6, 56.2, 27.8; HR-MS (ESI) 
m/z: calcd for C24H21BrFNO3S [M-Br]+ 422.1221, found 422.1228. 
(Z)-3-((1-(3-fluorobenzyl)piperidin-4-yl)methylene)-6,7-dimethoxyisothiochroma
n-4-one (15e). 
Yield 75.5 %, yellow solid; 1H NMR (300 MHz, CDCl3) δ 7.59 (s, 1H), 7.31 – 7.25 
(m, 1H), 7.12 (d, J = 2.3 Hz, 1H), 7.09 (s, 1H), 7.07 (d, J = 2.3 Hz, 1H), 6.99 – 6.91 
(m, 1H), 6.66 (s, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.87 (s, 2H), 3.51 (s, 2H), 2.92 – 2.85 
(m, 2H), 2.62 – 2.54 (m, 1H), 2.15 – 2.06 (m, 2H), 1.76 – 1.69 (m, 2H), 1.65 – 1.56 
(m, 2H); 13C NMR (75 MHz, CDCl3) δ 180.8, 164.0, 160.8, 152.1, 148.1, 143.9, 
140.8, 140.7, 134.5, 129.1, 129.0, 128.3, 125.6, 124.0, 124.0, 115.3, 115.1, 113.4, 
113.2, 111.0, 108.8, 62.4, 55.7, 55.6, 52.6, 36.7, 30.2, 28.7; HR-MS (ESI) m/z: calcd 
for C24H26FNO3S [M + H]
+ 428.1690, found 428.1695. 
(Z)-3-((1-(2-fluorobenzyl)piperidin-4-yl)methylene)-6,7-dimethoxyisothiochroma
n-4-one (15f). 
Yield 77.1 %, yellow solid; 1H NMR (300 MHz, CDCl3) δ 7.57 (s, 1H), 7.42 – 7.36 
(m, 1H), 7.26 – 7.20 (m, 1H), 7.13 (dd, J = 7.4, 1.3 Hz, 1H), 7.10 – 7.07 (m, 1H), 7.06 
– 7.00 (m, 1H), 6.65 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.86 (s, 2H), 3.61 (s, 2H), 2.96 
– 2.89 (m, 2H), 2.60 – 2.49 (m, 1H), 2.19 – 2.11 (m, 2H), 1.76 – 1.68 (m, 2H), 1.65 – 
1.55 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 181.3, 163.0, 159.8, 152.6, 148.6, 144.4, 
135.0, 131.6, 131.6, 128.8, 128.7, 128.6, 126.1, 124.9, 124.7, 123.8, 123.8, 115.3, 
115.0, 111.5, 109.3, 56.2, 56.1, 55.6, 52.8, 37.2, 30.7, 29.2; HR-MS (ESI) m/z: calcd 
for C24H26FNO3S [M + H]
+ 428.1690, found 428.1699.  
(Z)-1-benzyl-4-((6,7-dimethoxy-4-oxoisoselenochroman-3-ylidene)methyl)pyridin
-1-ium bromide (15g). 
Yield 49.5 %, yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 9.28 (s, 2H), 8.51 – 
8.32 (m, 2H), 8.29 (s, 1H), 7.60 (s, 2H), 7.47 (s, 3H), 7.39 (s, 1H), 7.12 (s, 1H), 5.91 
(s, 2H), 4.29 (s, 2H), 3.90 (s, 3H), 3.83 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 
180.5, 152.5, 151.3, 148.3, 144.5, 140.5, 135.5, 134.2, 130.0, 129.3, 129.2, 128.9, 
127.2, 125.5, 111.7, 110.9, 62.7, 56.1, 55.7, 20.9; HR-MS (ESI) m/z: calcd for 
C24H22BrNO3Se [M-Br]
+
 452.0759, found 452.0754. 
(Z)-4-((6,7-dimethoxy-4-oxoisoselenochroman-3-ylidene)methyl)-1-(4 
fluorobenzyl)pyridin-1-ium bromide (15h). 
Yield 50.2 %, yellow solid; 1H NMR (300 MHz, CDCl3) δ 9.57 (d, J = 6.2 Hz, 2H), 
8.09 (s, 1H), 8.06 (d, J = 6.0 Hz, 2H), 7.87 – 7.76 (m, 2H), 7.44 (s, 1H), 7.08 – 6.99 
(m, 2H), 6.80 (s, 1H), 6.29 (s, 2H), 4.10 (s, 2H), 3.97 (s, 3H), 3.92 (s, 3H);13C NMR 
(75 MHz, DMSO-d6) δ 181.0, 164.7, 161.4, 153.0, 151.9, 148.8, 144.9, 141.1, 135.9, 
132.1, 131.9, 130.9, 130.9, 130.4, 127.7, 126.0, 116.8, 116.5, 112.2, 111.4, 62.4, 56.6, 
56.2, 21.4; HR-MS (ESI) m/z: calcd for C24H21BrFNO3Se [M-Br]
+
 470.0665, found 
470.0668. 
(Z)-4-((6,7-dimethoxy-4-oxoisoselenochroman-3-ylidene)methyl)-1-(3 
fluorobenzyl)pyridin-1-ium bromide (15i). 
Yield 48.9 %, yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 9.27 (d, J = 6.3 Hz, 
2H), 8.36 (d, J = 6.2 Hz, 2H), 8.30 (s, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.49 – 7.42 (m, 
1H), 7.40 (s, 1H), 7.32 (d, J = 8.9 Hz, 1H), 7.13 (s, 1H), 5.92 (s, 2H), 4.30 (s, 2H), 
3.91 (s, 3H), 3.84 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 181.1, 153.0, 152.0, 
152.0, 148.8, 145.1, 141.2, 136.0, 136.0, 132.0, 131.8, 130.4, 127.7, 126.0, 125.6, 
125.5, 116.9, 116.7, 116.6, 116.3, 116.2, 115.9, 112.2, 111.4, 62.5, 56.6, 56.2, 21.4; 
HR-MS (ESI) m/z: calcd for C24H21BrFNO3Se [M-Br]
+
 470.0665, found 470.0665. 
(Z)-4-((6,7-dimethoxy-4-oxoisoselenochroman-3-ylidene)methyl)-1-(2-fluorobenz
yl)pyridin-1-ium bromide (15j). 
Yield 51.5 %, yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 9.16 (d, J = 6.4 Hz, 
2H), 8.35 (d, J = 6.4 Hz, 2H), 8.29 (s, 1H), 7.71 – 7.62 (m, 1H), 7.59 – 7.51 (m, 1H), 
7.42 – 7.35 (m, 2H), 7.33 (d, J = 7.7 Hz, 1H), 7.12 (s, 1H), 5.97 (s, 2H), 4.29 (s, 2H), 
3.90 (s, 3H), 3.83 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 181.0, 162.6, 159.4, 
153.0, 152.0, 148.8, 145.2, 141.4, 136.0, 132.7, 132.6, 132.0, 130.4, 127.7, 126.7, 
126.1, 126.0, 125.8, 121.8, 121.6, 116.7, 116.4, 112.2, 111.4, 57.9, 56.6, 56.1, 21.4; 
HR-MS (ESI) m/z: calcd for C24H21BrFNO3Se [M-Br]+ 470.0665, found 470.0674. 
(Z)-3-((1-(3-fluorobenzyl)piperidin-4-yl)methylene)-6,7-dimethoxyisoselenochro
man-4-one (15k). 
Yield 79.5 %, yellow solid; 1H NMR (300 MHz, CDCl3) δ 7.53 (s, 1H), 7.32 – 7.24 
(m, 2H), 7.11 – 7.03 (m, 2H), 6.97 – 6.89 (m, 1H), 6.66 (s, 1H), 3.94 (s, 3H), 3.92 (s, 
3H), 3.85 (s, 2H), 3.50 (s, 2H), 2.92 – 2.84 (m, 2H), 2.46 – 2.34 (m, 1H), 2.12 – 2.03 
(m, 2H), 1.72 – 1.65 (m, 2H), 1.65 – 1.54 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 
181.9, 164.0, 160.8, 151.5, 147.9, 146.3, 140.8, 140.7, 134.9, 129.1, 129.0, 126.9, 
124.8, 124.0, 124.0, 115.3, 115.1, 113.5, 113.2, 111.9, 109.3, 62.3, 55.6, 52.5, 39.1, 
30.1, 29.2, 20.0; HR-MS (ESI) m/z: calcd for C24H26FNO3Se [M+H]
+ 476.1135, 
found 476.1136.  
(Z)-3-((1-(2-fluorobenzyl)piperidin-4-yl)methylene)-6,7-dimethoxyisoselenochro
man-4-one (15l). 
Yield 78.8 %, yellow solid; 1H NMR (300 MHz, CDCl3) δ 7.52 (s, 1H), 7.42 – 7.35 
(m, 1H), 7.28 (d, J = 8.6 Hz, 1H), 7.26 – 7.19 (m, 1H), 7.14 – 7.08 (m, 1H), 7.07 – 
6.99 (m, 1H), 6.66 (s, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.85 (s, 2H), 3.60 (d, J = 1.5 Hz, 
2H), 2.97 – 2.89 (m, 2H), 2.44 – 2.32 (m, 1H), 2.18 – 2.09 (m, 2H), 1.72 (dd, J = 13.2, 
3.7 Hz, 2H), 1.66 – 1.54 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 182.5, 163.1, 159.8, 
152.0, 148.4, 146.9, 135.4, 131.7, 131.6, 128.8, 128.7, 127.4, 125.3, 124.8, 123.9, 
123.8, 115.4, 115.0, 112.3, 109.8, 100.0, 56.1, 56.1, 55.6, 52.7, 39.6, 30.6, 20.5; 
HR-MS (ESI) m/z: calcd for C24H26FNO3Se [M+H]
+ 476.1135, found 476.1142.  
AChE and BuChE inhibitory activity test assay 
Test samples were dissolved in DMSO as stock solutions of 10 mM and were 
diluted with buffer A to the proper concentration, and the concentration of DMSO in 
the solution did not exceeded 1%. In the 96-well plates, 30 μL of 
thioiodoacetylcholine (2 mM), 50 μL of AChE (0.22 U/mL, prepared with Buffer B) 
and 10 μL of different concentrations of inhibitors were mixed. The contents were 
incubated at 37 °C for 5 min, and then 30 μL of thioiodoacetylcholine (2 mM) was 
added to the mixture. After 1 min and 8 min, the reactions were terminated by 3 % 
SDS. The 160 μL of 0.2 % DTNB which was color agent was added. The linear 
increase in absorbance at 440 nM was measured after 0, 60, 120 and 180 s of 
incubation time. BuchE inhibition was assayed according to the similar method of 
AChE inhibition with minor modifications. Briefly, AChE needed to replace with 
BuChE (0.12 U/mL, prepared with Buffer B) and substrate iodoacetylcholine needed 
to replace with thioiodobenzoyl chloride (15 mM), other experimental conditions 
remain unchanged. 
Cell viability 
SH-SY5Y cells were planted in a 15 mL culture flask in Eagle's minimum essential 
medium (EMEM) and Ham's F-12 medium, supplemented with 10% fetal bovine 
serum, 100 U/mL penicillin and 100 μg/mL streptomycin, and the culture flask was 
cultured in the incubator (37 ℃, 5% CO2). The cells were then grown at 10
4 cells for 
per well in 96-well plates. When the cells were fused, the cells were placed in 
serum-free medium. The different concentrations of compounds 15a and 15h (1, 10, 
50 μM) were added to the serum-free medium which cultured for 24 h in the incubator, 
then 10 μL of MTT was added at 37 °C. After cultured for 3 h, 100 μL of DMSO was 
added to dissolve methanine crystals at the end, and the absorbance the mixture was 
determined at 490 nM by microplate reader. 
Kinetic study of AChE inhibition 
To obtain the mechanism of 15a, a series of experiments were performed by using 
Ellman’s method as same as AChE assay. 15a with concentration of 1.25 and 2.5 nM 
were selected for the kinetic analysis. Lineweaver-Burk reciprocal plots were 
constructed by plotting the 1 / velocity versus 1 / [substrate] at different concentration 
of substrate acetylthiocholine (0.05-0.5 mM) to obtain the type of inhibition. Data 
analysis was performed with GraphPad Prism 4.03 software. 
In vitro antioxidant activity assay 
  1,1-diphenyl-2-picryl-hydrazyl (DPPH) is commercially available organic nitrogen 
radicals which was used for the determination of free radical-scavenging activity of 
compounds 15a and 15h. The DPPH was dissolved in methanol to obtain a 0.1 mM 
concentration of DPPH stock solution. The 10 μL of the test samples at 100 μM and 
90 μL of DPPH solution were added to 96-well plates. After reacting for 30 min at 
25 ℃, the absorbance was recorded at 517 nM. And the trolox was applied as a 
reference. 
Molecular modeling  
In our study, the X-ray structure of the donepezil - AChE complex was downloaded 
from the Protein Data Bank (PDB code: 4ey7). The protein was prepared using 
Schrodinger. The docking procedure was performed by employing the Glide module 
in the Schrodinger software package, and the structural image was obtained using 
PyMOL software. 
In silico ADMETox study 
An in silico study of synthesized compounds 15a–15l was performed for 
prediction of ADME properties and toxicity. For this purpose, Blood–brain barrier 
(BBB) permeability, human intestinal absorption (HIA), Caco2 permeability (Caco2) 
and some toxicity risk parameters were calculated by using online admetSAR. 
Results & discussions 
Chemistry 
The synthetic route of the target compounds was shown in Figure 3. The iodination 
of the starting material 7 gave the intermediate 8 [16], which was substituted by ethyl 
2-mercaptoacetate in the presence of K2CO3 to afford intermediate 10a. The 
intermediate 9 was prepared by the reaction of intermediate 8 with newly prepared 
sodium selenide (Na2Se2), which was reduced by sodium borohydride (NaBH4) in 
MeOH and treated with ethyl 2-bromoacetate to give the intermediate 10b [17]. The 
intermediates 10a and 10b were hydrolyzed to give the corresponding acids 11a and 
11b, which were then cyclized via Friedel-crafts reactions to give isothiochromanone 
12a and isoselenochromanone 12b. Then, the key intermediates 12a and 12b reacted 
with pyridine-4-carboxaldehyde in the presence of 10% K2CO3 solution to give 
intermediates 13a and 13b. Intermediates 14a and 14b were synthesized by the 
similar methods using sodium methoxide as the base. Finally, compounds 13a, 13b, 
14a and 14b reacted with different benzyl bromide derivatives to yield the target 
compounds 15a - 15l. 
 
Figure 3. Reagents and conditions: (a) TMSCl, KI, CH3CN, rt, 45 min; (b) Se, NaBH4, H2O, rt, 30 
min; (c) ethyl 2-mercaptoacetate, K2CO3, acetone, rt, 5 h; (d) ethyl 2-bromoacetate, NaBH4, 
MeOH, 3 h; (e) 10% NaOH solution, MeOH, 80 ℃, 30 min; (f) i) oxalyl dichloride, DCM, 0 ℃, 
30 min; ii) SnCl4, chlorobenzene, rt, 2 h; (g) isonicotinaldehyde, K2CO3, H2O - DMF, 0 ℃, 30 s - 
2 min; (h) proper benzyl bromide derivatives, MeCN, reflux, 1 - 2 h; (i) i) NaOCH3, 
N-Boc-piperidine-4-carboxaldehyde, THF, rt, 1 - 5 min; ii), CF3COOH, DCM, rt, 2 h. 
In vitro inhibitory activity of cholinesterase 
The inhibitory activity of all target compounds against AChE and BuChE were 
evaluated using the spectrophotometric method of Ellman et al. And donepezil was 
used as a reference [18]. The IC50 values for the inhibition of AChE and BuChE were 
presented in Table 1. The results revealed that all target compounds bearing N-benzyl 
pyridinium moiety exhibit significant inhibitory activity towards AChE with IC50 
values in the nanomolar range, indicating that these compounds are potent AChE 
inhibitors. However, the AChE inhibitory activity of compounds 15e, 15f, 15k and 15l 
decreased significantly when pyridine was changed to piperidine, suggesting that the 
N-benzyl pyridinium moiety is crucial for AChE inhibition. The unsubstituted benzyl 
pyridinium compound 15a bearing an isothiochromanone moiety displayed the most 
potent inhibition against AChE with the IC50 value of 2.7 nM, which was 4.7-fold 
more potent than the positive control donepezil. The para-F substituted benzyl 
pyridinium compound 15h bearing isoselenochromanone moiety also displayed a 
potent inhibitory activity (IC50 = 5.8 nM), which was 2.2-fold more potent than 
donepezil. Thus, the potent AChE inhibitory activity of this class of derivatives 
prompted us to further investigate their kinetic and binding modes. 
Table 1. Inhibition of AChE and BuChE activities of the target compounds 
 
 
Compd. R R’ X 
IC50 (means ± SEM) a 
AChE (nM) BuChE (nM) 
15a H - S 2.7 ± 0.08 440 ± 180 
15b 4-F - S 11.9 ± 0.6 1440 ± 75 
15c 3-F - S 18.4 ± 0.8 2079 ± 102 
15d 2-F - S 9.8 ± 0.5 1480 ± 69 
15e - 3-F S 7470 ± 323 N.D b 
15f - 2-F S 8020 ± 356 N.D 
15g H - Se 9.9 ± 0.6 564 ± 31 
15h 4-F - Se 5.8 ± 0.3 609 ± 33 
15i 3-F - Se 11.9 ± 0.6 1059 ± 51 
15j 2-F - Se 9.6 ± 0.5 931 ± 45 
15k - 3-F Se 16400 ± 817 N.D 
15l - 2-F Se 15600 ± 781 N.D 
Donepezil - - - 12.7 ± 0.5 737 ± 37 
a IC50: 50% inhibitory concentration (means ± SEM of three experiments). 
b Not Determined. 
Kinetic study of AChE inhibition 
In order to analyze the AChE inhibitory mechanism of these inhibitors, the most 
potent compound 15a was selected for a kinetic test. The type of inhibition was 
elucidated from the analysis of Lineweaver–Burk reciprocal plots (Figure 4), which 
showed both increasing slopes and intercepts on the y-axis with increasing 
concentration of inhibitor. According to this pattern, compound 15a is a mixed-type 
inhibitor for AChE, which showed that compound 15a might be able to 
simultaneously bind to the CAS and PAS of AChE. 
 
Figure 4. Lineweaver-Burk plots resulting from subvelocity curve of AChE activity with different 
substrate concentrations in the absence and presence of 15a (0, 1.25, and 2.5 nM).  
Cell viability assay of compounds 15a and 15h 
To evaluate the cytotoxic effect of target compounds against nerve cell [19], the 
viability of SH-SY5Y cells treated with representative compounds 15a and 15h at 
different concentrations was determined. As shown in Table 2, negligible cytotoxicity 
was noted for compounds 15a and 15h at concentrations of 1 and 10 μM. When the 
concentration rose to 50 μM, the survival rate only decreased slightly (> 80%) and the 
morphology of the SH-SY5Y cells was not affected, which indicated that compounds 
15a and 15h have low neurotoxicity. 
 
Table 2. Cell viability of compounds 15a and 15h on nerve cells SH-SY5Y. 
Compounds Concentrations (μM) Cell viability (%) 
 1 99.6 ± 0.5 
15a 10 94.4 ± 0.9 
 50 88.7 ± 4.5 
 1 97.7 ± 0.7 
15h 10 95.2 ± 0.7 
 50 82.2 ± 0.8 
In vitro antioxidant activity 
  The radical scavenging activity of compounds 15a and 15h was determined by 
using 1,1-diphenyl-2-picryl-hydrazyl (DPPH) assay and trolox was used as a 
reference. The results showed that compounds 15a and 15h at a concentration of 100 
μM possessed moderate antioxidant activity. The free radical scavenging activity of 
compounds 15a and 15h were 55% and 45% compared to trolox, respectively, which 
were more potent than that of compound 6 (10%). 
Docking studies 
To further explore the binding mode of compounds 15a and 15h with AChE, a 
molecular docking study was performed by using the Glide module in the Schrodinger 
software package. The X-ray crystal structure of AChE complexed with donepezil 
(PDB: 4ey7) was chosen as the docking protein. As shown in Figure 5, the overlay of 
the best poses of docked compounds 15a and 15h with donepezil in the active site 
clearly demonstrated that compounds 15a and 15h adopt similar dual-binding modes 
to that of donepezil in the binding pocket. As presented, the methoxy groups and 
carbonyl group of isothio- and isoselenochromanone moieties formed three hydrogen 
bonds with a water molecule (H2O953) and the residue Phe295 of PAS, respectively. 
Isothio- and isoselenochromanone moieties showed π - π stacking interactions with 
Trp286, which is another important amino acid residue of PAS. In addition, the 
N-benzyl pyridinium moiety of compounds 15a and 15h bound to the CAS of AChE 
via aromatic π - π stacking interactions and salt bridge with Trp86 and Asp74, 
respectively. All these results indicated that compounds 15a and 15h could 
simultaneously bind to the PAS and CAS of AChE, which is in accordance with the 
results of kinetic study. 
 
Figure 5. A) The docking mode of compound 15a (cyan) and donepezil (yellow) with AChE; B) 
The docking mode of compound 15h (purple) and donepezil with AChE. The hydrogen bonds of 
ligands with the target were shown by red dashed line. 
Prediction of toxicity risks and drug-likeness properties 
To evaluate the drug-likeness character of the target compounds, toxicity risks 
(mutagenicity, tumorigenicity, irritation, and reproduction) were predicted by Osiris 
calculation. Moreover, the ADME (Absorption, Distribution, Metabolism, and 
Excretion) properties of the target compounds, such as BBB (Blood–Brain Barrier) 
penetration, HIA (Human Intestinal Absorption), Caco-2 cell permeability were also 
calculated using admetSAR web-based application [20]. As shown in Table 3, 
compounds 15a-f bearing isothiochromanone moiety were predicted to be without 
toxicity risks, whereas compounds 15g-l bearing isoselenochromanone moiety were 
tumorigenic. According to the predicted values for BBB, all compounds might be able 
to penetrate into the central nervous system (CNS). In the case of HIA and Caco-2 
permeability, all compounds might be well absorbed from intestine. 
Table 3. Osiris calculations and ADMET properties prediction of all compounds and donepezil. 
Compd. 
Toxicity Risks a ADMET properties 
MUT TUM IRRIT RE BBB b HIA c Caco-2 d 
15a     + + + 
15b     + + + 
15c     + + + 
15d     + + + 
15e     + + + 
15f     + + + 
15g     + + + 
15h     + + + 
15i     + + + 
15j     + + + 
15k     + + + 
15l     + + + 
donepezil     + + + 
a MUT: mutagenic; TUM: tumorigenic; IRRIT: irritant; RE: reproductive effective, green 
represents non-toxic and red represents toxic. 
b Blood Brain Barrier. The values more than 95 was considered as +. 
c Human Intestinal Absorption. The values more than 90 was considered as +. 
d The values more than 50 was considered as +. 
Conclusion 
  In conclusion, on the basis of our previous studies, twelve novel AChE inhibitors 
bearing N-benzyl pyridinium moiety derived from natural product XJP were further 
designed and synthesized. Most of the target compounds possessed potent AChE 
inhibitory activity. Among the synthesized compounds, compound 15a displayed the 
most potent anti-AChE activity (IC50 = 2.7 nM), moderate antioxidant activity and low 
neurotoxicity. Moreover, according to the kinetic and docking studies, compound 15a 
was proved to be a mixed-type inhibitor binding to the PAS and CAS of AChE. All 
these results highlighted 15a was a promising lead compound for the development of 
anti-AD agents. 
Future perspective 
  Alzheimer disease (AD), which has become a health problem worldwide, is the 
most common form of dementia in elderly people. However, the pathogenesis of AD 
still remains unclear. And the approved drug (donepezil, rivastigmine, galantamine 
and memantine) could only enable a palliative treatment instead of curing or 
preventing AD. Therefore, it is necessary to develop new and more effective anti-AD 
drugs. 
  Based on the results of our studies, most of the isothio- and isoselenochromanone 
derivatives were potent AChE inhibitors. Therefore, we speculate that isothio- and 
isoselenochromanone are desirable skeletons which could provide new insights into 
the development of anti-AD drugs.  
Executive summary 
Introduction: 
● Alzheimer's disease (AD), which emerged as the main cause of dementia, has 
affected over 46 million elderly people in the worldwide. 
Experimental section: 
● A series of novel isothio- and isoselenochromanone derivatives were 
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